Tag Archives: Shreeram Aradhye

(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release →